Denali Therapeutics Inc. Common Stock

DNLINASDAQ • USD
ThemeBiotech - Drug Development›Neuroscience & CNS
20.38 USD
↘ 0.84 (3.96%)AT CLOSE (11:59 AM EDT)
21.05
↗ 0.67 (3.29%)
POST MARKET (AS OF 06:47 PM EDT)
Post Market
AS OF 06:47 PM EDT
21.05
↗ 0.67 (3.29%)
🟢Market: OPEN

DNLI is currently priced at $21.05. The technical outlook is "Sell" and the fundamental picture shows "Neutral". Key drivers include a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, DNLI is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Sep 15, 2026.

Open?$21.01
High?$21.10
Low?$20.27
Prev. Close?$21.22
Volume?1.8M
Avg. Volume?1.3M
VWAP?$20.44
Rel. Volume?1.45x
Bid / Ask
Bid?$17.18 × 100
Ask?$24.23 × 100
Spread?$7.05
Midpoint?$20.71
Valuation & Ratios
Market Cap?3.4B
Shares Out?159.8M
Float?133.1M
Float %?83.3%
P/E Ratio?N/A
P/B Ratio?4.06
EPS?-$3.21
Dividend?0.00%
Ex-Dividend?N/A
RelatedBEAM
News
Profile
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Themes
Biotech - Drug Development›Neuroscience & CNSLongevity & Aging›Age-Related Therapeutics
Employees
507
Market Cap
3.4B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.denalitherapeutics.com
Listed
2017-12-08
Address
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 866-8547
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
60
Momentum?
77
Short Sent.?
53
Piotroski F-Score?0/9Weak
Altman Z-Score?2.66Grey
Confidence?54%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?12.50%High
Short Interest?16.6M
Days to Cover?17.5
Free Float133.1M
Avg Daily Volume951.2K
Settlement Date2026-08-31
Financial Health
Current Ratio?8.37Strong
Quick Ratio?8.32Strong
Cash Ratio?2.24Strong
Debt/Equity?0.01Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
50
S&P
44
4.06FAIR▾
P/S?
Peers
50
S&P
3
941.17HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-6.0CHEAP▾
EV/Sales?
Peers
50
S&P
3
886.77HIGH▾
Returns & Efficiency
ROE?
S&P
3
-61.4%WEAK▾
ROA?
S&P
3
-44.3%WEAK▾
Cash Flow & Enterprise
FCF?$-437457000
Enterprise Value?$3.2B
Fundamentals ratios updated end of day
MarketsMoversWatchlist